Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05062330 · ClinicalTrials.gov registry record · Phase 3
The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease
A Phase 3 study of Dry Eye, sponsored by Aldeyra Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 361
- Enrollment target
- 1
- Study location
NCT05062330 is a Phase 3 study of Dry Eye that has completed, run by Aldeyra Therapeutics. The registered enrollment target is 361 participants, above the 87-participant average among 41 other Dry Eye trials with a reported enrollment target (315% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05062330, a Phase 3 study of Dry Eye, has completed, sponsored by Aldeyra Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 361 participants
- Enrollment target
- 1
- Study location
Study Summary
The TRANQUILITY 2 Trial: Multi-Center Randomized, Double-Masked, Parallel Design, Vehicle-Controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease
Conditions Studied
Interventions
- DRUG Vehicle Ophthalmic Solution
- DRUG Reproxalap Ophthalmic Solution (0.25%)
Study Locations (1)
Massachusetts
- Andover Eye Associates (Raynham) - Raynham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 361 participants |
| Start Date | 2021-08-28 |
| Est. Completion | 2022-03-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05062330
The ClinicalTrials.gov registry entry for NCT05062330 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 361 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 87-participant average among 41 other Dry Eye trials with a reported enrollment target (315% higher). The listed sponsor is Aldeyra Therapeutics, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dry Eye appearing as the primary indexed condition, and to 2 interventions - of which Vehicle Ophthalmic Solution is the first listed.
NCT05062330 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05062330 about?
NCT05062330 is a clinical study titled "The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease". The TRANQUILITY 2 Trial: Multi-Center Randomized, Double-Masked, Parallel Design, Vehicle-Controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease
What is the current status of trial NCT05062330?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 361 participants. The study started on 2021-08-28. Estimated completion is 2022-03-04.
What conditions does trial NCT05062330 study?
This clinical trial studies the following conditions: Dry Eye.
What interventions are being tested in trial NCT05062330?
The interventions under investigation include: Vehicle Ophthalmic Solution (DRUG), Reproxalap Ophthalmic Solution (0.25%) (DRUG).
Who is sponsoring clinical trial NCT05062330?
This trial is sponsored by Aldeyra Therapeutics, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05062330 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
COMPLETED · Phase 3
-
Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study)
COMPLETED · Phase 3
-
Efficacy of Kera Sol Tears on Signs and Symptoms of Surgical Temporary Ocular Discomfort Syndrome (STODS) in Subjects Following LASIK
RECRUITING · Phase 4
-
The THINK Study Incidence of Neurotrophic Keratopathy)
RECRUITING · NA
-
Low Level Light Therapy & Skin Pigmentation
RECRUITING · NA
-
Quality of Life in Presbyopic Patients Who Are Treated With Qlosi
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.